Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cleveland BioLabs, Inc. stock logo
CBLI
Cleveland BioLabs
$0.00
$3.19
$1.62
$10.97
$11K0.7271,922 shs5,001 shs
Celyad Oncology SA stock logo
CYAD
Celyad Oncology
$0.60
$0.67
$0.46
$3.07
$15.91MN/AN/A3,009 shs
Merrimack Pharmaceuticals, Inc. stock logo
MACK
Merrimack Pharmaceuticals
$14.73
+0.1%
$14.71
$11.53
$15.89
$214.03M1.43110,413 shs82,390 shs
MusclePharm Co. stock logo
MSLP
MusclePharm
$0.00
$0.00
$0.00
$7K-0.0726,442 shsN/A
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
$4.96
-2.0%
$5.54
$4.05
$9.94
$89.53M-0.2945,544 shs9,841 shs
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cleveland BioLabs, Inc. stock logo
CBLI
Cleveland BioLabs
0.00%+16.67%+16.67%+16.67%-97.05%
Celyad Oncology SA stock logo
CYAD
Celyad Oncology
0.00%0.00%0.00%0.00%-15.71%
Merrimack Pharmaceuticals, Inc. stock logo
MACK
Merrimack Pharmaceuticals
-0.14%+0.20%-0.14%+10.60%+21.57%
MusclePharm Co. stock logo
MSLP
MusclePharm
0.00%0.00%0.00%0.00%-53.85%
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
-1.94%-19.30%-18.39%+2.64%-34.54%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Cleveland BioLabs, Inc. stock logo
CBLI
Cleveland BioLabs
N/AN/AN/AN/AN/AN/AN/AN/A
Celyad Oncology SA stock logo
CYAD
Celyad Oncology
N/AN/AN/AN/AN/AN/AN/AN/A
Merrimack Pharmaceuticals, Inc. stock logo
MACK
Merrimack Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
MusclePharm Co. stock logo
MSLP
MusclePharm
N/AN/AN/AN/AN/AN/AN/AN/A
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
2.0026 of 5 stars
3.52.00.00.03.61.70.0

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cleveland BioLabs, Inc. stock logo
CBLI
Cleveland BioLabs
N/AN/AN/AN/A
Celyad Oncology SA stock logo
CYAD
Celyad Oncology
N/AN/AN/AN/A
Merrimack Pharmaceuticals, Inc. stock logo
MACK
Merrimack Pharmaceuticals
N/AN/AN/AN/A
MusclePharm Co. stock logo
MSLP
MusclePharm
N/AN/AN/AN/A
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
3.00
Buy$11.00121.77% Upside

Current Analyst Ratings

Latest CBLI, PRPH, CYAD, MSLP, and MACK Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
2/21/2024
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$11.00
(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cleveland BioLabs, Inc. stock logo
CBLI
Cleveland BioLabs
$260K0.04N/AN/A$0.87 per share0.00
Celyad Oncology SA stock logo
CYAD
Celyad Oncology
$110K144.65N/AN/A$0.20 per share3.00
Merrimack Pharmaceuticals, Inc. stock logo
MACK
Merrimack Pharmaceuticals
N/AN/AN/AN/A$1.31 per shareN/A
MusclePharm Co. stock logo
MSLP
MusclePharm
$50.04M0.00N/AN/A($0.94) per share0.00
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
$44.38M2.02N/AN/A$2.74 per share1.81

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cleveland BioLabs, Inc. stock logo
CBLI
Cleveland BioLabs
-$2.40MN/A0.00N/AN/A-32.84%-31.29%N/A
Celyad Oncology SA stock logo
CYAD
Celyad Oncology
-$9.14MN/A0.00N/AN/AN/AN/AN/A
Merrimack Pharmaceuticals, Inc. stock logo
MACK
Merrimack Pharmaceuticals
-$1.18M-$0.08N/AN/AN/A-6.24%-6.09%5/2/2024 (Estimated)
MusclePharm Co. stock logo
MSLP
MusclePharm
-$12.87M-$0.58N/AN/AN/A-38.51%N/A-169.56%N/A
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
-$16.78M-$0.98N/AN/A-37.81%-29.83%-18.14%5/9/2024 (Estimated)

Latest CBLI, PRPH, CYAD, MSLP, and MACK Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/28/2024Q4 2023
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
N/A-$0.51-$0.51-$0.51$10.71 million$3.50 million
3/7/2024Q4 2023
Merrimack Pharmaceuticals, Inc. stock logo
MACK
Merrimack Pharmaceuticals
N/A-$0.01-$0.01-$0.01N/AN/A

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Cleveland BioLabs, Inc. stock logo
CBLI
Cleveland BioLabs
N/AN/AN/AN/AN/A
Celyad Oncology SA stock logo
CYAD
Celyad Oncology
N/AN/AN/AN/AN/A
Merrimack Pharmaceuticals, Inc. stock logo
MACK
Merrimack Pharmaceuticals
N/AN/AN/AN/AN/A
MusclePharm Co. stock logo
MSLP
MusclePharm
N/AN/AN/AN/AN/A
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cleveland BioLabs, Inc. stock logo
CBLI
Cleveland BioLabs
N/A
45.93
45.93
Celyad Oncology SA stock logo
CYAD
Celyad Oncology
N/AN/AN/A
Merrimack Pharmaceuticals, Inc. stock logo
MACK
Merrimack Pharmaceuticals
N/A
43.50
43.50
MusclePharm Co. stock logo
MSLP
MusclePharm
N/A
0.25
0.23
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
0.29
2.28
2.10

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Cleveland BioLabs, Inc. stock logo
CBLI
Cleveland BioLabs
5.09%
Celyad Oncology SA stock logo
CYAD
Celyad Oncology
N/A
Merrimack Pharmaceuticals, Inc. stock logo
MACK
Merrimack Pharmaceuticals
63.97%
MusclePharm Co. stock logo
MSLP
MusclePharm
15.49%
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
9.45%

Insider Ownership

CompanyInsider Ownership
Cleveland BioLabs, Inc. stock logo
CBLI
Cleveland BioLabs
1.03%
Celyad Oncology SA stock logo
CYAD
Celyad Oncology
0.94%
Merrimack Pharmaceuticals, Inc. stock logo
MACK
Merrimack Pharmaceuticals
28.87%
MusclePharm Co. stock logo
MSLP
MusclePharm
60.70%
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
26.10%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Cleveland BioLabs, Inc. stock logo
CBLI
Cleveland BioLabs
415.48 millionN/ANot Optionable
Celyad Oncology SA stock logo
CYAD
Celyad Oncology
9526.52 million26.28 millionNot Optionable
Merrimack Pharmaceuticals, Inc. stock logo
MACK
Merrimack Pharmaceuticals
42614.53 million10.34 millionOptionable
MusclePharm Co. stock logo
MSLP
MusclePharm
2733.39 million13.12 millionNot Optionable
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
11318.05 million13.34 millionOptionable

CBLI, PRPH, CYAD, MSLP, and MACK Headlines

SourceHeadline
ProPhase Labs to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 & 1x1 Meetings on Thursday, May 2, 2024ProPhase Labs to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 & 1x1 Meetings on Thursday, May 2, 2024
globenewswire.com - April 25 at 8:00 AM
Diamond Equity Equities Analysts Cut Earnings Estimates for ProPhase Labs, Inc. (NASDAQ:PRPH)Diamond Equity Equities Analysts Cut Earnings Estimates for ProPhase Labs, Inc. (NASDAQ:PRPH)
marketbeat.com - April 25 at 7:37 AM
ProPhase Labs, Inc. (NASDAQ:PRPH) to Post Q1 2025 Earnings of $0.10 Per Share, Diamond Equity ForecastsProPhase Labs, Inc. (NASDAQ:PRPH) to Post Q1 2025 Earnings of $0.10 Per Share, Diamond Equity Forecasts
americanbankingnews.com - April 25 at 2:21 AM
Equities Analysts Set Expectations for ProPhase Labs, Inc.s Q1 2025 Earnings (NASDAQ:PRPH)Equities Analysts Set Expectations for ProPhase Labs, Inc.'s Q1 2025 Earnings (NASDAQ:PRPH)
marketbeat.com - April 24 at 6:32 AM
ProPhase Labs (NASDAQ:PRPH) Stock Price Crosses Above Two Hundred Day Moving Average of $5.00ProPhase Labs (NASDAQ:PRPH) Stock Price Crosses Above Two Hundred Day Moving Average of $5.00
americanbankingnews.com - April 23 at 4:44 AM
ProPhase Labs Shares Jump on New AI-Based ProjectProPhase Labs Shares Jump on New AI-Based Project
marketwatch.com - April 16 at 3:52 PM
ProPhase Labs Unveils Project ZenQ-AIProPhase Labs Unveils Project ZenQ-AI
globenewswire.com - April 16 at 8:00 AM
PRISM MarketView – Biotech BreakfastPRISM MarketView – Biotech Breakfast
prismmediawire.com - April 15 at 8:29 AM
ProPhase Labs, Inc.: ProPhase Labs Seeks to Transform Esophageal Cancer Detection and Management with Launch of its BE-Smart Test in H2 2024ProPhase Labs, Inc.: ProPhase Labs Seeks to Transform Esophageal Cancer Detection and Management with Launch of its BE-Smart Test in H2 2024
finanznachrichten.de - April 10 at 10:26 AM
ProPhase Flat on Cancer Drug ProgressProPhase Flat on Cancer Drug Progress
baystreet.ca - April 10 at 10:26 AM
ProPhase Labs Seeks to Transform Esophageal Cancer Detection and Management with Launch of its BE-Smart Test in H2 2024ProPhase Labs Seeks to Transform Esophageal Cancer Detection and Management with Launch of its BE-Smart Test in H2 2024
globenewswire.com - April 10 at 8:00 AM
ProPhase Labs Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)ProPhase Labs Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com - April 1 at 9:00 PM
ProPhase Labs, Inc. (PRPH)ProPhase Labs, Inc. (PRPH)
finance.yahoo.com - April 1 at 1:09 AM
Short Interest in ProPhase Labs, Inc. (NASDAQ:PRPH) Declines By 16.9%Short Interest in ProPhase Labs, Inc. (NASDAQ:PRPH) Declines By 16.9%
marketbeat.com - March 30 at 9:21 AM
ProPhase Labs (NASDAQ:PRPH) Stock Price Crosses Above 200-Day Moving Average of $4.77ProPhase Labs (NASDAQ:PRPH) Stock Price Crosses Above 200-Day Moving Average of $4.77
marketbeat.com - March 29 at 3:21 AM
D2C Pavilion at Startup Mahakumbh Sets the Stage for Vibrant ConversationsD2C Pavilion at Startup Mahakumbh Sets the Stage for Vibrant Conversations
itnewsonline.com - March 18 at 7:29 PM
Foundation Software Helps California Contractors Maintain ComplianceFoundation Software Helps California Contractors Maintain Compliance
itnewsonline.com - March 18 at 2:29 PM
ProPhase Labs, Inc. (NASDAQ:PRPH) Q4 2023 Earnings Call TranscriptProPhase Labs, Inc. (NASDAQ:PRPH) Q4 2023 Earnings Call Transcript
finance.yahoo.com - March 18 at 9:29 AM
PRPH Stock Earnings: ProPhase Labs Misses EPS, Misses Revenue for Q4 2023PRPH Stock Earnings: ProPhase Labs Misses EPS, Misses Revenue for Q4 2023
msn.com - March 15 at 1:48 PM
ProPhase Labs Announces Financial Results for the Year Ended December 31, 2023 and Significant Progress in Its Strategic InitiativesProPhase Labs Announces Financial Results for the Year Ended December 31, 2023 and Significant Progress in Its Strategic Initiatives
globenewswire.com - March 15 at 8:00 AM
ProPhase Labss Earnings: A PreviewProPhase Labs's Earnings: A Preview
benzinga.com - March 14 at 2:34 PM
Down 34% and 57%, Wall Street Says These 2 Stocks Will Gain 230%Down 34% and 57%, Wall Street Says These 2 Stocks Will Gain 230%
msn.com - March 12 at 7:21 PM
PROPHASE LABS TO PRESENT 2023 YEAR END FINANCIAL RESULTS ON MARCH 15, 2024PROPHASE LABS TO PRESENT 2023 YEAR END FINANCIAL RESULTS ON MARCH 15, 2024
globenewswire.com - March 8 at 8:00 AM
ProPhase Labs, Inc. (NASDAQ:PRPH) Shares Could Be 29% Above Their Intrinsic Value EstimateProPhase Labs, Inc. (NASDAQ:PRPH) Shares Could Be 29% Above Their Intrinsic Value Estimate
finance.yahoo.com - March 1 at 8:32 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Cleveland BioLabs logo

Cleveland BioLabs

NASDAQ:CBLI
Cytocom, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel small molecule immunotherapies. Its product applies to autoimmune, inflammatory, infectious diseases and cancers. The company was founded by Andrei V. Gudkov and Yakov Kogan on June 5, 2003 and is headquartered in Fort Collins, CO.
Celyad Oncology logo

Celyad Oncology

NASDAQ:CYAD
Celyad Oncology SA is a clinical-stage biotechnology company, which focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. It operates through the following segments: Cardiology and Immuno-Oncology. The Cardiology segment includes the company's Cardiopoiesis, Corquest, and C-Cathez platforms. The Immuno-Oncology segment consists of all assets developed based on the CAR-T cell platform. The company was founded by Michel Lussier, William Wijns, and Christian Homsy on July 24, 2007 and is headquartered in Mont-Saint-Guibert, Belgium.
Merrimack Pharmaceuticals logo

Merrimack Pharmaceuticals

NASDAQ:MACK
Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company in the United States. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.
MusclePharm logo

MusclePharm

OTCMKTS:MSLP
MusclePharm Corporation develops, manufactures, markets, and distributes sports nutrition products and nutritional supplements in the United States and internationally. The company offers a range of performance powders, capsules, tablets, gels, and on-the-go ready to eat snacks. Its MusclePharm brand product portfolio includes combat protein powder and combat crunch protein bars; and essential supplements, such as a BCAA, creatine, glutamine, carnitine, CLA, fish oil, multi-vitamin, and other products. The company also provides FitMiss branded sports nutrition products, which are formulated primarily for the female body to support women in the areas of weight management, lean muscle mass, body composition, and general health and wellness; and functional energy beverages under the Combat Energy and FitMiss Energy brands. It sells its products to various athletes and fitness enthusiasts. The company was incorporated in 2006 and is based in Las Vegas, Nevada.
ProPhase Labs logo

ProPhase Labs

NASDAQ:PRPH
ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. It also offers contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; COVID-19 diagnostic information services to a range of customers, including health plans, third party payers, and government organizations; and respiratory pathogen panel molecular testing services, as well as personal genomics products and services. In addition, the company involved in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements; and retail operations. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.